Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Mark E Polhemus"'
Autor:
Aileen Kenneson, Efraín Beltrán-Ayala, Mercy J Borbor-Cordova, Mark E Polhemus, Sadie J Ryan, Timothy P Endy, Anna M Stewart-Ibarra
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 11, Iss 12, p e0006150 (2017)
BACKGROUND:In Ecuador, dengue virus (DENV) infections transmitted by the Aedes aegypti mosquito are among the greatest public health concerns in urban coastal communities. Community- and household-level vector control is the principal means of contro
Externí odkaz:
https://doaj.org/article/3b56950195354d7a98ec745205c9b237
Autor:
Jason W Bennett, Anjali Yadava, Donna Tosh, Jetsumon Sattabongkot, Jack Komisar, Lisa A Ware, William F McCarthy, Jessica J Cowden, Jason Regules, Michele D Spring, Kristopher Paolino, Joshua D Hartzell, James F Cummings, Thomas L Richie, Joanne Lumsden, Edwin Kamau, Jittawadee Murphy, Cynthia Lee, Falgunee Parekh, Ashley Birkett, Joe Cohen, W Ripley Ballou, Mark E Polhemus, Yannick F Vanloubbeeck, Johan Vekemans, Christian F Ockenhouse
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 2, p e0004423 (2016)
A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric
Externí odkaz:
https://doaj.org/article/1d1246902c114fc3828a7b9030188e30
Autor:
James J Moon, Heikyung Suh, Mark E Polhemus, Christian F Ockenhouse, Anjali Yadava, Darrell J Irvine
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31472 (2012)
The parasite Plasmodium vivax is the most frequent cause of malaria outside of sub-Saharan Africa, but efforts to develop viable vaccines against P. vivax so far have been inadequate. We recently developed pathogen-mimicking polymeric vaccine nanopar
Externí odkaz:
https://doaj.org/article/5726c7a94356494d90ee816fdf40c14a
Autor:
Naomi E Aronson, Glenn W Wortmann, William R Byrne, Robin S Howard, Wendy B Bernstein, Mary A Marovich, Mark E Polhemus, In-Kyu Yoon, Kelly A Hummer, Robert A Gasser, Charles N Oster, Paul M Benson
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 4, Iss 3, p e628 (2010)
BackgroundCutaneous Leishmania major has affected many travelers including military personnel in Iraq and Afghanistan. Optimal treatment for this localized infection has not been defined, but interestingly the parasite is thermosensitive.Methodology/
Externí odkaz:
https://doaj.org/article/c04558007a874f7c8881f817483cce86
Autor:
John N Waitumbi, Samuel B Anyona, Carol W Hunja, Carolyne M Kifude, Mark E Polhemus, Douglas S Walsh, Chris F Ockenhouse, D Gray Heppner, Amanda Leach, Marc Lievens, W Ripley Ballou, Joe D Cohen, Colin J Sutherland
Publikováno v:
PLoS ONE, Vol 4, Iss 11, p e7849 (2009)
RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. T
Externí odkaz:
https://doaj.org/article/a9ea83d041ba4d49905fd441eed46a9e
Autor:
Mark E Polhemus, Shon A Remich, Bernhards R Ogutu, John N Waitumbi, Lucas Otieno, Stella Apollo, James F Cummings, Kent E Kester, Christian F Ockenhouse, Ann Stewart, Opokua Ofori-Anyinam, Isabelle Ramboer, Conor P Cahill, Marc Lievens, Marie-Claude Dubois, Marie-Ange Demoitie, Amanda Leach, Joe Cohen, W Ripley Ballou, D Gray Heppner
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6465 (2009)
BackgroundThis study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria endemic populations. As a primary objective it compares the safety and reactogenicity of RTS,S/AS01B to the more extensively evaluated RTS,
Externí odkaz:
https://doaj.org/article/84c5f3aac3754964900009e529047c9f
Autor:
Cantalloube C, Bernhards Ogutu, Otsula N, Peter G. Kremsner, Apollo D, Walsh Ds, Elhadj Djeriou, Christian Supan, Ghyslain Mombo-Ngoma, John N. Waitumbi, Mark E. Polhemus, Bertrand Lell, Ospina Salazar Cl, Maryvonne Kombila, Jana Held
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 97:514-525
Artemisinin-based combination therapies are recommended as first-line agents for treating uncomplicated Plasmodium falciparum malaria. Ferroquine, a 4-aminoquinolone, is a novel long-acting combination partner for fast-acting drugs like artesunate (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190a3698fb7436eff546231f74cbb659
https://doi.org/10.4269/ajtmh.16-0731
https://doi.org/10.4269/ajtmh.16-0731
Publikováno v:
Journal of Infectious Diseases. 209:S40-S45
Background Since 1986, investigators at Walter Reed Army Institute of Research (WRAIR) have been using controlled human malaria challenge (CHMI) in malaria-naive adults in order to define the protective efficacy of a malaria vaccine and thus guide pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1835853f17e033694a22dc396596b44f
https://doi.org/10.1093/infdis/jiu063
https://doi.org/10.1093/infdis/jiu063
Autor:
Megan Dowler, Alan F. Cowman, Christian F. Ockenhouse, Sebastian A. Mikolajczak, Jack Williams, Mark E. Polhemus, Stasya Zarling, Jason W. Bennett, Patricia de la Vega, Olivia C. Finney, Stefan H. I. Kappe, D. Gray Heppner, Cindy L. Tamminga, Michele D. Spring, Jack Komisar, Matthew T. O'Neill, Urszula Krzych, Robin Nielsen, Hannah Smithers, Judy Epstein, Lisa A. Ware, Ruobing Wang, Thomas L. Richie, Jittawadee Murphy, Michael O’Neil, Julie Healer, Ilin Chuang, Nancy Richie
Publikováno v:
Vaccine. 31:4975-4983
Background Immunization with genetically engineered, attenuated malaria parasites (GAP) that arrest during liver infection confers sterile protection in mouse malaria models. A first generation Plasmodium falciparum GAP ( Pf p52 − /p36 − GAP) was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::696db6b9963c10dc1eace6ffdd029a5e
https://doi.org/10.1016/j.vaccine.2013.08.007
https://doi.org/10.1016/j.vaccine.2013.08.007
Autor:
Joanne M. Lumsden, Mark E. Polhemus, Steven G. Reed, Anjali Yadava, Saule Nurmukhambetova, Kosol Yongvanitchit, Jetsumon Sattabongkot, Amporn Limsalakpetch, Jason W. Bennett, Sathit Pichyangkul, Jennifer H. Klein, Thomas S. Vedvick, Sylvie Bertholet, Randall F. Howard, Utaiwan Srichairatanakul, Christian F. Ockenhouse
Publikováno v:
Infection and Immunity. 79:3492-3500
Plasmodium vivax is the major cause of malaria outside sub-Saharan Africa and inflicts debilitating morbidity and consequent economic impacts in developing countries. In order to produce a P. vivax vaccine for global use, we have previously reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ec42aacd211879184bc81baf0e584dd
https://doi.org/10.1128/iai.05257-11
https://doi.org/10.1128/iai.05257-11